RE: SloneHi KayDay: Why wouldn't we be excited about the testing at Sloan Kettering? I don't believe they are just repeating the same tests over and over again. They have now chosen to target the specific cancer types Ovarian and Melanoma and have testing on both simultaneously at two different centers. In addition, Gary Schwartz is on their clinical trial advisory board so I am sure any work he does will be beneficial in taking the compound towards clinical trials. To me that doesn't sound like a bad strategy. If this doesn't get you excited, what would?